Enzon Pharmaceuticals (ENZN)
Enzon Pharmaceuticals, Inc. CEO Andrew Rackear to Retire; Richard L. Feinstein, Enzon’s CFO, to Assume Position of CEO and Remain CFO
Enzon Pharmaceuticals Announces Results of Rights Offering
Looking to Next Step – Acquisition Opportunities
Enzon Pharmaceuticals Announces Key Dates for Rights Offering
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
CRANFORD, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (the “Company” or “Enzon”) (OTC:ENZN) today announced that its 20...
Enzon Pharmaceuticals, Inc. Announces Postponement of 2020 Annual Meeting
Enzon Pharmaceuticals' board approves rights offering (OTCMKTS:ENZN)
Under the board approved rights offering to existing shareholders, Enzon Pharmaceuticals' (OTC:ENZN) seeks to distribute one transferable subscription right for each outstanding share of common stock owned.For every 1,105 subscription rights held, a shareholder will be entitled to purchase one unit.Enzon plans to offer 40K units at a subscription price of $1,090/unit; each unit will consist of one preferred share par value $1,000, and 750 common stock shares.With no voting rights, preferred stock holders will be entitled to receive cumulative dividends at the rate per share of 3% p.a., if paid in cash, or 5% p.a., if paid in-kind.
Enzon Pharmaceuticals Anticipated Rights Offering to Existing Shareholders
Enzon Pharmaceuticals, Inc. Adopts Tax Benefits Preservation Plan to Protect its NOL Assets and Shareholder Value